← Back to Search

Behavioural Intervention

WhatsApp for Increase Retention of First-time Blood Donors (C-CAD Trial)

N/A

Recruiting

Research Sponsored by University of Minnesota

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

First-time whole blood donor with the SZBC of the NBSG

At least 18 years-old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 14 months

Awards & highlights

C-CAD Trial Summary

This trial will study the effectiveness of using WhatsApp groups or docudrama compared to usual engagement with blood services on getting people to donate blood again in Ghana. The trial will have three groups: one using

Who is the study for?

This trial is for first-time blood donors in Ghana who are at least 18 years old, understand English, Twi, or Ga, have a smartphone with WhatsApp or are willing to sign up for it. They must be eligible to donate again and agree to watch a docudrama on blood donation.Check my eligibility

What is being tested?

The study tests if using WhatsApp groups or watching a docudrama can encourage first-time blood donors in Ghana to keep donating. It compares these methods against the usual communication from blood services over 14 months.See study design

What are the potential side effects?

There may not be direct medical side effects from participating; however, participants might experience inconvenience due to time spent in WhatsApp groups or watching docudramas.

C-CAD Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am a first-time blood donor at the SZBC of the NBSG.

Select...

I am 18 years old or older.

C-CAD Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 14 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~14 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 14 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Proportion with a repeat donation attempt

C-CAD Trial Design

3Treatment groups

Experimental Treatment

Active Control

Group I: docudramaExperimental Treatment1 Intervention

Participants randomized to this arm will meet three times (Month 2; Month 5 and Month 10), in a group setting, during the intervention. Each group will have a maximum of 20-40 participants. This is a stand-alone activity, which is not associated with a donation event. During each meeting, participants will be asked to watch, in the group setting, an episode of drama, lasting 15 minutes. The docudrama on blood donation will address participant's concerns regarding blood donation and address common donor fears.

Group II: WhatsAppExperimental Treatment1 Intervention

Participants assigned to the WhatsApp arm will receive messages, audios, images and videos in a moderated, closed WhatsApp group over a 14-month duration. The messages aim to motivate blood donation, encourage participants to discuss their blood donation experiences, and allow them to share their motivations for donating blood.

Group III: controlActive Control1 Intervention

standard of care for repeat blood donation

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

2021

N/A

~280

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

National Blood Service GhanaUNKNOWN

3 Previous Clinical Trials

859 Total Patients Enrolled

Liverpool School of Tropical MedicineOTHER

85 Previous Clinical Trials

717,228 Total Patients Enrolled

National Heart, Lung, and Blood Institute (NHLBI)NIH

3,840 Previous Clinical Trials

47,851,242 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Which criteria must individuals meet in order to be considered eligible for participation in this trial?

"This research study aims to enroll 882 individuals, with a specific focus on enhancing the retention of first-time blood donors between the ages of 18 and 65. Prospective participants must meet several noteworthy criteria including being at least 18 years old, providing informed consent, having proficiency in either English, Twi or Ga languages, possessing a smartphone, agreeing to have an active WhatsApp account or sign up for one if necessary, expressing willingness to watch a docudrama on blood donation within a group setting. Additionally, they should be first-time whole blood donors under the supervision of SZBC (National Blood Service Ghana) and eligible for further donations"

Answered by AI

Is the enrollment process ongoing for this medical study?

"Indeed, the data available on clinicaltrials.gov indicates that this trial is presently enlisting patients. The initial posting of the study occurred on December 15th, 2023, and it was last revised on January 4th, 2024. In order to complete the research successfully, a total of 882 participants are being sought from a single designated site."

Answered by AI

What is the current number of participants involved in this clinical study?

"Indeed, the information found on clinicaltrials.gov indicates that this study is actively seeking participants. The trial was originally posted on December 15th, 2023 and most recently updated on January 4th, 2024. A total of 882 patients are being sought for enrollment from a single site."

Answered by AI

Is the age criterion for participation in this medical study limited to individuals below 80 years of age?

"Participants must be of legal adult age, which is defined as 18 years or older. Additionally, individuals should not exceed the age of 65 to meet the eligibility requirements for this clinical trial."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Community-based Communication for Blood Donation in Ghana

2024. "Community-based Communication for Blood Donation in Ghana". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05973890.